Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Found 117 products of "Bcr-Abl"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formula:C26H29Cl2N5O3Purity:98.98% - 99.9%Color and Shape:Yellowish-Orange Or Pink To Brownish Solid Solid PowderMolecular weight:530.45Imatinib Mesylate
CAS:Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,
Formula:C29H31N7O·CH4SO3Purity:98% - >99.99%Color and Shape:White Crystalline PowderMolecular weight:589.71Dasatinib
CAS:Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.Formula:C22H26ClN7O2SPurity:99.59% - 99.86%Color and Shape:Pale-Yellow SolidMolecular weight:488.01Nilotinib
CAS:Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Formula:C28H22F3N7OPurity:99.89% - >99.99%Color and Shape:Off-White SolidMolecular weight:529.52N-Desmethyl imatinib
CAS:N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formula:C28H29N7OPurity:98.60%Color and Shape:Off-White To Pale-Yellow SolidMolecular weight:479.58Ref: TM-T11641
1mg87.00€5mg166.00€10mg303.00€25mg512.00€50mg737.00€100mg1,018.00€1mL*10mM (DMSO)170.00€AKE-72
CAS:AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Formula:C30H29F3N6OPurity:98.3%Color and Shape:SoildMolecular weight:546.59Ref: TM-T80676
1mg88.00€2mg129.00€5mg212.00€10mg310.00€25mg479.00€50mg642.00€100mg880.00€200mg1,161.00€LXH254
CAS:LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formula:C25H25F3N4O4Purity:98.3% - 99.92%Color and Shape:SolidMolecular weight:502.49Ref: TM-T11898
1mg52.00€5mg122.00€10mg185.00€25mg363.00€50mg567.00€100mg690.00€200mg948.00€500mg1,444.00€1mL*10mM (DMSO)135.00€Lyn-IN-1
CAS:Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and LynFormula:C30H31F3N8OPurity:97% - 98.02%Color and Shape:SolidMolecular weight:576.62Ref: TM-T11916
1mg38.00€2mg50.00€5mg79.00€10mg117.00€25mg236.00€50mg371.00€100mg530.00€200mg770.00€1mL*10mM (DMSO)92.00€Dasatinib monohydrate
CAS:Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.Formula:C22H28ClN7O3SPurity:99.68% - >99.99%Color and Shape:SolidMolecular weight:506.03ML 2-23
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].Formula:C47H53BrCl2N10O7SPurity:98%Color and Shape:SolidMolecular weight:1052.86SIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formula:C50H62ClN11O6S2Purity:98.07%Color and Shape:SolidMolecular weight:1012.68Ref: TM-T12907
1mg152.00€5mg356.00€10mg485.00€25mg888.00€50mg1,431.00€100mg2,052.00€200mg2,673.00€1mL*10mM (DMSO)393.00€c-ABL-IN-5
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability,Formula:C19H17F2N3OPurity:98%Color and Shape:SolidMolecular weight:341.35FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidPROTAC BCR-ABL1 ligand 1
CAS:GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formula:C17H12F3N3O2Color and Shape:SoildMolecular weight:347.29SNIPER(ABL)-047
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,Formula:C67H82F3N11O9SPurity:98%Color and Shape:SolidMolecular weight:1274.5BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Formula:C20H17ClF2N4O3SColor and Shape:SolidMolecular weight:466.89SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formula:C44H59ClN10O8SPurity:98%Color and Shape:SolidMolecular weight:923.52SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurity:98%Color and Shape:SolidMolecular weight:1177.85DPH
CAS:DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formula:C18H13FN4O2Purity:99.65%Color and Shape:SolidMolecular weight:336.32FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formula:C28H26Cl2N4O3Color and Shape:SolidMolecular weight:537.44SNIPER(ABL)-013
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 ofFormula:C42H52F3N7O8Purity:98%Color and Shape:SolidMolecular weight:839.9SNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Formula:C58H70F3N9O9Purity:98%Color and Shape:SolidMolecular weight:1094.23SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Formula:C68H84N12O9Purity:98%Color and Shape:SolidMolecular weight:1213.47SNIPER(ABL)-039
CAS:SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 ofFormula:C54H68ClN11O9S2Purity:98%Color and Shape:SolidMolecular weight:1114.77Imatinib impurities3
CAS:Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.
Formula:C24H20ClN5OPurity:98.63%Color and Shape:SolidMolecular weight:429.9SNIPER(ABL)-033
CAS:SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL proteinFormula:C61H73F3N10O9S2Purity:98%Color and Shape:SolidMolecular weight:1211.42SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFormula:C51H64F3N9O8SPurity:98%Color and Shape:SolidMolecular weight:1020.17MRT-7612
MRT-7612 (Compound 4) is a cereblon-based molecular glue degrader targeting tyrosine kinases. It significantly induces the degradation of HCK and LYN, with a comparatively weaker effect on LCK. MRT-7612 is applicable in research related to cancers such as chronic myeloid leukemia, autoimmune disorders, and chronic inflammatory diseases.Color and Shape:Odour SolidcSRC/BCR-ABL-IN-1
cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.Formula:C29H31Cl2N5O4Color and Shape:SolidMolecular weight:584.494Tyrosine kinase-IN-8
Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI) exhibiting antiproliferative activity against the chronic myeloid leukemia (CML) cell line K562, with a CC50 of 0.8 µM. Tyrosine kinase-IN-8 is applicable for research in chronic leukemia.Formula:C31H21F2N7O2Molecular weight:561.17248Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireTyrosine Kinase Inhibitor Library
A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase relatedColor and Shape:Odour SolidRef: TM-L2200
1mgTo inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireAbl Cytosolic Substrate
CAS:Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formula:C64H101N15O16Purity:98%Color and Shape:SolidMolecular weight:1336.58SNIPER(ABL)-058
CAS:SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL proteinFormula:C62H75N11O9SPurity:98%Color and Shape:SolidMolecular weight:1150.39PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormula:C43H40N10O6Purity:98%Color and Shape:SolidMolecular weight:792.84c-ABL-IN-1
CAS:C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's diseaseFormula:C17H16Cl2FN3OSColor and Shape:SolidMolecular weight:400.29SNIPER(ABL)-049
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,Formula:C52H66N10O8Purity:98%Color and Shape:SolidMolecular weight:959.14SIAIS100 TFA
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].Formula:C46H51ClF5N9O7SPurity:98%Color and Shape:SolidMolecular weight:1004.46SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurity:98%Color and Shape:SolidMolecular weight:1031.15SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColor and Shape:SolidMolecular weight:890.44BCR-ABL-IN-10
BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).Formula:C24H22N4O5SColor and Shape:SolidMolecular weight:478.52cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formula:C24H27ClN6O4Color and Shape:SolidMolecular weight:498.96BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Color and Shape:SolidMolecular weight:388.42TG-100435
CAS:TG-100435 is a novel multi-target oral protein tyrosine kinase inhibitor. The metabolic flux of TG100435 is entirely inhibited by methimazole and ketoconazole. In human liver microsomes or recombinant P450, the formation of TG100435 increases with the activity of cytochrome P450 reductase, suggesting that cytochrome P450 reductase may be involved.Formula:C26H25Cl2N5OColor and Shape:SolidMolecular weight:494.42HG-7-85-01-NH2
CAS:HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].Formula:C27H27F3N6OSColor and Shape:SolidMolecular weight:540.6AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44Asciminib hydrochloride
CAS:Asciminib hydrochloride is a STAMP inhibitor targeting the ABL myristoyl pocket, applied in Ph+ CML research for selective oncogenic signaling modulation.Formula:C20H19Cl2F2N5O3Purity:99.91%Color and Shape:SolidMolecular weight:486.3Ref: TM-T63226
1mg57.00€5mg130.00€10mg177.00€25mg289.00€50mg409.00€100mg620.00€1mL*10mM (DMSO)138.00€Flumatinib mesylate
CAS:Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.Formula:C30H33F3N8O4SPurity:99.82%Color and Shape:SolidMolecular weight:658.69Ref: TM-T7861
1mg34.00€5mg84.00€10mg126.00€25mg236.00€50mg371.00€100mg595.00€500mg1,234.00€1mL*10mM (DMSO)132.00€GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purity:97.05% - 99.7%Color and Shape:SolidMolecular weight:547.53Degrasyn
CAS:Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formula:C19H18BrN3OPurity:98.32% - 99.98%Color and Shape:SolidMolecular weight:384.27Ref: TM-T6300
2mg42.00€5mg60.00€10mg92.00€25mg188.00€50mg324.00€100mg505.00€200mg710.00€1mL*10mM (DMSO)66.00€Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurity:98% - 99.91%Color and Shape:Physical Description White Powder (Ntp 1992)Molecular weight:301.32Ref: TM-T2802
5mg34.00€10mg52.00€25mg94.00€50mg165.00€100mg268.00€200mg399.00€500mg647.00€1mL*10mM (DMSO)38.00€Rebastinib
CAS:DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,
Formula:C30H28FN7O3Purity:99.53% - 99.79%Color and Shape:SolidMolecular weight:553.59Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurity:98% - 99.60%Color and Shape:SolidMolecular weight:532.56NVP-BAW2881
CAS:NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.Formula:C22H15F3N4O2Purity:98.19% - 99.97%Color and Shape:SolidMolecular weight:424.38Ref: TM-T3641
1mg34.00€2mg48.00€5mg71.00€10mg109.00€25mg200.00€50mg324.00€100mg470.00€500mg1,054.00€1mL*10mM (DMSO)69.00€AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formula:C20H17F3N4O3Purity:99.34%Color and Shape:SolidMolecular weight:418.37Ref: TM-T4191
1mg37.00€2mg52.00€5mg79.00€10mg101.00€25mg177.00€50mg268.00€100mg385.00€1mL*10mM (DMSO)87.00€Flumatinib
CAS:Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formula:C29H29F3N8OPurity:99.39% - 99.95%Color and Shape:SolidMolecular weight:562.59Ref: TM-T4320
1mg34.00€5mg63.00€10mg82.00€25mg120.00€50mg155.00€100mg259.00€200mg388.00€500mg642.00€1mL*10mM (DMSO)82.00€AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurity:98% - 99.37%Color and Shape:SolidMolecular weight:305.17Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurity:97.66% - >99.99%Color and Shape:SolidMolecular weight:724.77Ref: TM-T2429
1mg37.00€5mg79.00€10mg113.00€25mg216.00€50mg289.00€100mg378.00€200mg552.00€1mL*10mM (DMSO)114.00€Dasatinib N-oxide
CAS:Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.
Formula:C22H26ClN7O3SPurity:98.54% - 99.94%Color and Shape:SolidMolecular weight:504Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formula:C29H27F3N6OPurity:98.53% - >99.99%Color and Shape:SolidMolecular weight:532.56Ref: TM-T3071
1mg34.00€2mg43.00€5mg63.00€10mg95.00€25mg190.00€50mg304.00€100mg416.00€1mL*10mM (DMSO)73.00€NVP-BHG712
CAS:NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src andFormula:C26H20F3N7OPurity:97.32% - 98.63%Color and Shape:SolidMolecular weight:503.48Ref: TM-T6348
1mg34.00€5mg74.00€10mg105.00€25mg200.00€50mg371.00€100mg557.00€200mg790.00€1mL*10mM (DMSO)84.00€Agerafenib
CAS:Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.Formula:C24H22F3N5O5Purity:95.78% - 99.23%Color and Shape:SolidMolecular weight:517.46Ref: TM-T2070
1mg39.00€5mg93.00€10mg124.00€25mg219.00€50mg358.00€100mg530.00€200mg757.00€1mL*10mM (DMSO)90.00€GNF-2
CAS:GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.Formula:C18H13F3N4O2Purity:98.17% - ≥95%Color and Shape:SolidMolecular weight:374.32GMB-475
CAS:GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.Formula:C43H46F3N7O7SPurity:98.78% - >99.99%Color and Shape:SolidMolecular weight:861.93Ref: TM-T8488
1mg50.00€2mg66.00€5mg99.00€10mg160.00€25mg281.00€50mg416.00€100mg600.00€200mg835.00€1mL*10mM (DMSO)152.00€KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Formula:C20H20N4OPurity:98.43% - 99.69%Color and Shape:SolidMolecular weight:332.4BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formula:C30H29F3N6O3Purity:98.21% - >99.99%Color and Shape:SolidMolecular weight:578.58Ref: TM-T4618
1mg58.00€2mg82.00€5mg113.00€10mg178.00€25mg333.00€50mg477.00€100mg692.00€1mL*10mM (DMSO)145.00€Asciminib
CAS:Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
Formula:C20H18ClF2N5O3Purity:98.82% - 99.70%Color and Shape:SolidMolecular weight:449.84Ref: TM-T5177
1mg63.00€2mg92.00€5mg127.00€10mg187.00€25mg305.00€50mg427.00€100mg630.00€500mg1,320.00€Imatinib
CAS:Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kitFormula:C29H31N7OPurity:99.42% - 99.94%Color and Shape:Off White PowderMolecular weight:493.6Vodobatinib
CAS:Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.Formula:C27H20ClN3O2Purity:99.06% - 99.55%Color and Shape:SolidMolecular weight:453.92Ref: TM-T8882
1mg34.00€5mg74.00€10mg110.00€25mg200.00€50mg323.00€100mg500.00€500mg1,209.00€1mL*10mM (DMSO)82.00€XL228
CAS:XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Formula:C22H31N9OPurity:99.07%Color and Shape:SolidMolecular weight:437.54Ref: TM-T17267
1mg52.00€2mg73.00€5mg94.00€10mg141.00€25mg244.00€50mg371.00€100mg552.00€1mL*10mM (DMSO)104.00€Bafetinib
CAS:Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.Formula:C30H31F3N8OPurity:94.16% - 99.68%Color and Shape:SolidMolecular weight:576.62Ref: TM-T6311
1mg34.00€2mg49.00€5mg74.00€10mg98.00€25mg150.00€50mg178.00€100mg333.00€200mg432.00€1mL*10mM (DMSO)95.00€GNF-5
CAS:GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Formula:C20H17F3N4O3Purity:98% - 99.94%Color and Shape:SolidMolecular weight:418.37CZC-8004
CAS:CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
Formula:C17H16FN5Purity:99.29%Color and Shape:SolidMolecular weight:309.34Adaphostin
CAS:Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Formula:C24H27NO4Purity:98.29%Color and Shape:SolidMolecular weight:393.48Nilotinib monohydrochloride monohydrate
CAS:Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosineFormula:C28H22F3N7O·HCl·H2OPurity:99.93%Color and Shape:SolidMolecular weight:583.99AST 487
CAS:AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Formula:C26H30F3N7O2Purity:98.17% - 99.56%Color and Shape:SolidMolecular weight:529.56Ref: TM-T4053
1mg34.00€2mg49.00€5mg74.00€10mg113.00€25mg177.00€50mg334.00€100mg500.00€500mg1,099.00€1mL*10mM (DMSO)87.00€PD173955
CAS:PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR andFormula:C21H16Cl2N4OSPurity:98.52% - 98.99%Color and Shape:SolidMolecular weight:443.35Ref: TM-T3063
2mg35.00€5mg50.00€10mg92.00€25mg166.00€50mg248.00€100mg371.00€200mg530.00€1mL*10mM (DMSO)94.00€Bosutinib hydrate
CAS:Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Formula:C26H31Cl2N5O4Purity:99.87%Color and Shape:SolidMolecular weight:548.46c-ABL-IN-3
CAS:c-ABL-IN-3, from patent WO2021048567A1, is a potent c-Abl inhibitor for researching ALS, PD, and cancer.Formula:C17H11F3N4O3Color and Shape:SolidMolecular weight:376.29CHMFL-ABL-053
CAS:CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.Formula:C28H26F3N7O2Color and Shape:SolidMolecular weight:549.55c-ABL-IN-4
CAS:c-ABL-IN-4 is a potent inhibitor of c-Abl.Formula:C18H11ClF3N3O3Color and Shape:SolidMolecular weight:409.75AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Formula:C19H14F3N3O2Color and Shape:SolidMolecular weight:373.33BCR-ABL1-IN-1
CAS:BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.Formula:C18H12F3N3O2Color and Shape:SolidMolecular weight:359.3AP 24149
CAS:AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.Formula:C23H24N5OPColor and Shape:SolidMolecular weight:417.44BCR-ABL-IN-7
CAS:BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Formula:C19H16FN3O3SPurity:98.28%Color and Shape:SolidMolecular weight:385.41CpCDPK1/TgCDPK1-IN-1
CAS:CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.Formula:C18H17N5Purity:99.61%Color and Shape:SolidMolecular weight:303.36Antiproliferative agent-30
CAS:Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM againstFormula:C24H26N4O4Color and Shape:SolidMolecular weight:434.49PF-06651481-00
CAS:PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.
Formula:C26H29Cl2N5O3Purity:97.01%Color and Shape:SolidMolecular weight:530.45BCR-ABL-IN-1
CAS:BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Formula:C23H21F4N5OPurity:98%Color and Shape:SolidMolecular weight:459.44BCR-ABL-IN-2
CAS:BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).Formula:C24H25Cl2N5O3Purity:98%Color and Shape:SolidMolecular weight:502.39AN-019
CAS:AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.Formula:C25H17F6N5OPurity:98.99%Color and Shape:SolidMolecular weight:517.43c-ABL-IN-2
CAS:C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.Formula:C21H20N4OColor and Shape:SolidMolecular weight:344.41BGB659
CAS:BGB659 is effective inhibitor of RAF.Formula:C29H29F3N4O3Purity:98%Color and Shape:SolidMolecular weight:538.56Tyrphostin AG 568
CAS:Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.Formula:C13H9N5O2Purity:98%Color and Shape:SolidMolecular weight:267.24ON 146040
CAS:ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.Formula:C24H23N7O3SPurity:97.39%Color and Shape:SolidMolecular weight:489.55Ref: TM-T12310
1mg46.00€5mg96.00€10mg156.00€25mg245.00€50mg344.00€100mg460.00€200mg622.00€1mL*10mM (DMSO)104.00€Debio 0617B
CAS:Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.Formula:C28H23ClF3N7O2Color and Shape:SolidMolecular weight:581.98PD-173956
CAS:PD-173956 is an inhibitor of the Src family tyrosine kinases.Formula:C20H13Cl2FN4OColor and Shape:SolidMolecular weight:415.25BCR-ABL-IN-6
CAS:BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Formula:C25H21Cl2N5O2Color and Shape:SolidMolecular weight:494.37
